Zach Reitano on Ro's 10x growth via GLP-1s, culture reset, and healthcare's future
Summary
Zach Reitano argues healthcare should be 50% of GDP, citing misaligned incentives where patients are not the customers. He details Ro's turnaround from a 'zombie company' to a $3B+ run rate through a 'strong attract, strong repel' culture and operational efficiency. Reitano predicts GLP-1s will see 50%+ US penetration, driving prices down via direct-to-consumer models. He contrasts this with AI, noting GLP-1 revenue exceeds AI revenue and impacts more individuals. Reitano advocates for prioritizing health outcomes over job preservation and leveraging AI to make concierge care a commodity.
Episode sections
- 0:00 – 1:42
Sponsor Reads and Advertisements
The segment begins with sponsor reads for Ramp, Rogo, and WorkOS, followed by the host's introduction of the guest and topic.
- 1:42 – 3:35
Healthcare GDP and Systemic Flaws
Zach Reitano argues healthcare should be 50% of GDP, citing Jevons paradox and the US's 18% spend. He identifies the core flaw as the patient not being the customer, with incentives misaligned between providers, payers, and patients.
- 3:35 – 10:40
GLP-1s and Direct-to-Consumer Economics
Reitano discusses the state of US healthcare, noting high acute care quality but rising chronic disease. He highlights GLP-1s as a model for direct-to-consumer care, where removing PBMs and insurers drives prices down (e.g., from $1,300 to $149) while increasing manufacturer revenue.
- 10:40 – 16:31
Ro's Business Model and Growth
Ro operates in four categories: cardiometabolic, sexual health, dermatology, and fertility. Reitano notes growth from a $250M to over $3B run rate with fewer employees, driven by GLP-1s. He emphasizes vertical integration and continuous innovation as key differentiators.
- 16:31 – 23:18
GLP-1 Market Penetration and Societal Impact
Reitano predicts 50%+ of Americans will use GLP-1s within 10-15 years, citing high obesity rates and metabolic health data. He argues GLP-1s are rewiring the healthcare system by empowering patients to vote with their feet, forcing price transparency and competition.
- 23:18 – 26:27
Outcomes Over Inputs and Job Displacement
Reitano advocates prioritizing health outcomes over job preservation, using driverless cars as an analogy. He criticizes regulators for impeding safe technology due to job displacement concerns, arguing society must accept that new technologies will displace old ones if they are substantially better.
- 26:27 – 29:24
GLP-1 Revenue vs. AI and Company Turnaround
Reitano notes GLP-1 revenue exceeds AI revenue and that more individuals pay for GLP-1s than use AI, highlighting a gap in consumer impact for AI. The segment concludes with the host asking about Ro's turnaround and growth story.
- 29:24 – 38:36
Ro's 2021-2022 Refounding and Culture Reset
Zach Reitano describes Ro's 2021 performance as a 'zombie company' with 9% growth despite a $5B valuation and $500M raise. In late 2021, he initiated a 'strong attract, strong repel' culture shift, leading to the departure of ~20% of staff and seven VPs in early 2022 to align with high-performance standards.
- 38:36 – 44:11
Operational Efficiency and Sequential Focus
Reitano attributes Ro's 10x growth with 30% fewer staff to a combination of industry tailwinds and internal operational changes. Key strategies included doubling down on top talent, eliminating parallel projects in favor of sequential focus, and holding daily leadership meetings to reduce context switching.
- 44:11 – 46:39
The 'Patient Revolution' and Healthcare Tailwinds
Reitano identifies three tailwinds for healthcare: biology data coming online (genetics, wearables), AI replacing specialists with prompts, and new treatments like GLP-1s. He predicts healthcare could eventually cost as much as a Netflix subscription due to these efficiencies.
- 46:39 – 54:09
Personal Health Stack and PCSK9 Innovation
Reitano shares his personal health regimen, which reduced his LDL from 130 to 10 using statins, Zetia, Repatha, and GLP-1s. He highlights the Dallas Heart Study and the recent approval of an oral PCSK9 peptide by Merck as examples of AI/data-driven medical breakthroughs.
- 54:09 – 1:00:38
Inspiration from Father and Wife's Journalism
Reitano explains his motivation to 'recreate his dad' through software, aiming to scale the personalized care his father provided as a doctor. He also discusses his wife's YouTube channel, 'Huge If True,' noting her realization that she was 'born to explain things' to change lives.
- 1:00:38 – 1:02:17
Marketing Strategy and Stigma
Reitano explains Ro's strategy of starting with patient 'want' rather than just 'need' to activate consumers in healthcare. He discusses using celebrity ambassadors like Serena Williams and Megan Fox to create 'permission structures' that reduce stigma around weight loss and sexual health.
- 1:02:17 – 1:17:44
Operational Model and AI Integration
Ro uses Large Language Models to analyze patient messages, structuring side effect reports and routing them to healthcare providers with a 24/7 sub-30-minute response time. Reitano emphasizes that the company takes risks on behalf of patient outcomes and publishes data on side effect response times.
Assets discussed
| Asset | Kind | Stance | Context |
|---|---|---|---|
| AppleAAPL | equity | neutral | if the companies you love stayed still, Apple, Amazon, Google, wherever it may be, if they stay still for six. or 12 months, you see this even in the AI races. |
| AmazonAMZN | equity | neutral | if the companies you love stayed still, Apple, Amazon, Google, wherever it may be, if they stay still for six. or 12 months, you see this even in the AI races. |
| AlphabetGOOGL | equity | neutral | if the companies you love stayed still, Apple, Amazon, Google, wherever it may be, if they stay still for six. or 12 months, you see this even in the AI races. |
“Stance” is how the speakers talked about the asset, not a recommendation.
Claims worth verifying
Ro raised $500 million at a $5 billion valuation in January 2021.
Unidentified speaker (speaker_1) ·29:39
How to verify: SEC EDGAR filing Form D or press releases from January 2021 regarding Ro's Series C funding. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Primary sourceRo had an $800 million preferred stack.
Unidentified speaker (speaker_1) ·30:19
How to verify: SEC EDGAR filing Form D or investor presentations from 2021 detailing capitalization table and preferred equity terms. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Primary sourceRo grew 9% in 2021.
Unidentified speaker (speaker_1) ·30:19
How to verify: Internal company reports or press releases from 2026 discussing 2021 performance metrics. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Ro refounded the company in summer 2022, with decisions made in December 2021.
Unidentified speaker (speaker_1) ·29:24
How to verify: Company blog posts or press releases from 2022 announcing the cultural reset and rebranding from Roman to Ro. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Ro moved on from about seven VPs from January to May 2022.
Unidentified speaker (speaker_1) ·32:39
How to verify: LinkedIn profiles of former Ro VPs showing departure dates in early 2022 or company announcements. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Ro moved on from about 20% of the organization in May to June 2022.
Unidentified speaker (speaker_1) ·32:39
How to verify: Internal company announcements or LinkedIn activity of former employees departing in mid-2022. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Ro has grown 100% year-over-year for the last four years (as of 2026).
Unidentified speaker (speaker_1) ·36:13
How to verify: Ro's financial disclosures, investor updates, or press releases from 2026-2026 showing revenue growth. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Ro has 400 employees, down from 600+ in 2022.
Unidentified speaker (speaker_1) ·36:33
How to verify: LinkedIn company page employee count or internal headcount reports from 2026. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Reitano's LDL went from 130 to 10 using statins, Zetia, Repatha, and GLP-1.
Unidentified speaker (speaker_1) ·49:06
How to verify: Personal medical records (private) or public statements/interviews where Reitano cites these specific numbers. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Primary sourceDallas Heart Study started in 2000 with 3,500 patients.
Unidentified speaker (UNKNOWN) ·52:15
How to verify: Published academic papers or NIH records for the Dallas Heart Study initiated in 2026. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Ro grew from a $250 million run rate to over $3 billion in four years.
Unidentified speaker (speaker_0) ·1:00:05
How to verify: Company press releases or financial filings if/when public; third-party business news reports from 2026-2026. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Primary sourceRo has fewer employees now than it had in 2021.
Unidentified speaker (speaker_0) ·1:00:05
How to verify: LinkedIn employee count trends for Ro Health; company press releases regarding layoffs or restructuring. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Ro publishes data on side effect response times.
Unidentified speaker (speaker_1) ·1:02:17
How to verify: Ro Health website or published white papers/reports on their site; SEC filings if public. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Primary sourceRo has a 24/7 sub-30-minute response time for side effects.
Unidentified speaker (speaker_1) ·1:02:17
How to verify: Ro Health terms of service or patient experience documentation; independent verification via patient reviews or company reports. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Serena Williams is an ambassador for Ro Body for GLP-1.
Unidentified speaker (speaker_2) ·1:03:42
How to verify: Ro Health press releases or marketing materials featuring Serena Williams; public announcements. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Primary sourceMegan Fox was featured in a Ro campaign for erectile dysfunction.
Unidentified speaker (speaker_1) ·1:04:03
How to verify: Ro Health advertising campaigns; press coverage of the Megan Fox Ro commercial. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Alcohol is described as an exchange of poison for entertainment.
Unidentified speaker (UNKNOWN) ·1:10:13
How to verify: Transcript of the podcast episode. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Ro's co-founder is Simon.
Unidentified speaker (speaker_1) ·1:07:37
How to verify: Ro Health leadership page; SEC filings if public; business directories. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Primary sourceZach Reitano met his spouse Cleo when he was 19 and she was 17.
Unidentified speaker (speaker_1) ·1:11:59
How to verify: Public interviews or biographical information about Zach Reitano. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Zach Reitano's father had a fourth heart attack while driving him home from boarding school.
Unidentified speaker (speaker_1) ·1:13:57
How to verify: Transcript of the podcast episode; public interviews where this story is recounted. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Do your own research
- Verify Ro's financials: Check SEC filings (S-1 or 10-K) for revenue growth, headcount changes, and cash reserves to confirm the $3B run rate and 30% staff reduction claims.
- Assess GLP-1 market penetration: Review CDC obesity data and pharmaceutical sales reports to validate the prediction of 50%+ US usage within 10-15 years.
- Evaluate Ro's competitive moat: Analyze competitor pricing (e.g., Hims, Hers, Nurx) and patient acquisition costs to test the claim of vertical integration driving prices down to $149.
- Check GLP-1 safety data: Review FDA adverse event reports and clinical studies for side effect profiles to assess the 'probabilistic risk-benefit' claim versus alcohol.
- Verify AI healthcare claims: Investigate Merck's oral PCSK9 peptide approval status and Dallas Heart Study data to confirm the 'AI/data-driven breakthrough' assertions.
- Analyze cultural impact: Review Glassdoor or LinkedIn employee sentiment for Ro to assess the 'strong attract, strong repel' culture's effect on retention and performance.
- Compare AI vs. GLP-1 revenue: Consult public company earnings reports (e.g., Novo Nordisk, Eli Lilly, Meta, Microsoft) to verify the claim that GLP-1 revenue exceeds AI revenue.
- Assess regulatory risks: Review FDA and FTC guidelines on direct-to-consumer pharmaceutical marketing to evaluate the sustainability of Ro's celebrity ambassador strategy.
Full transcriptexpand
- 0:00
- Unidentified speaker (speaker_0): Ramp is the only platform built to make your finance team leaner, faster, and better, saving businesses 5% annually on average so you can stay focused on growth. Ramp customers grow 3.2 times faster than the average American business. Visa for sell, cursor, stripe, and 70,000 other businesses all run on Ramp. Mine does too, and so should yours. Learn more at
- 0:20
- Unidentified speaker (speaker_0): ramp.com.
- 0:22
- Unidentified speaker (speaker_0): Rogo is the AI platform purpose-built for financial institutions serving 10%. tens of thousands of bankers and investors at hundreds of leading firms worldwide. Rogo's AI agents autonomously execute large chunk of your firm's workflows. They can screen deals, draft sims, run buyer outreach, and due diligence on data rooms, all with full security and
- 0:42
- Unidentified speaker (speaker_0): compliance handle. Every action feeds Rogo Intelligence, the firm's context layer, turning years of deal experience into a secure, governed institutional memory. that makes each new transaction stronger than the last. To learn more, visit rogo.com/slash invest.
- 0:58
- Unidentified speaker (speaker_0): OpenAI, Cursor, Anthropic, Perplexity, and Vercell all have something in common. They all use Work OS. And here's why. To achieve enterprise adoption at scale, you have to deliver on core capabilities like SSO, Skim, RBAC, and Audit Logs. That's where WorkOS comes in. Instead of spending months
- 1:17
- Unidentified speaker (speaker_0): building these mission critical capabilities yourself, you can just use WorkOS APIs to gain all of them on day zero. That's why so many of the top AI teams you hear about already run on WorkOS. Work OS is the fastest way to become enterprise ready and stay focused on what matters most: your product. Visit workOS.com to get started.
- 1:42
- Unidentified speaker (speaker_0): I've got a first question based on our last phone call, which was something you told me, which just really stood out. What percent of GDP do you think healthcare could or should be 10, 15 years from now?
- 1:55
- Unidentified speaker (speaker_1): I think it should be as high as possible. 57
- 1:57
- Unidentified speaker (speaker_2): Rose's
- 1:58
- Unidentified speaker (speaker_0): always complaining
- 1:58
- Unidentified speaker (speaker_2): it's it's too too high. high.
- 1:59
- Unidentified speaker (speaker_1): Everyone's always complaining it's too high. And I think that it's missing the forest for the trees. If you think about healthcare, I think it's the sine qua nan of life. It's without which there is none. And it's actually depends how AI built you are, but your audience is probably pretty AI built. But if you imagine a life of pure abundance and you imagine Jevon's paradox does its thing,
- 2:19
- Unidentified speaker (speaker_1): then the only good in our lives that does not have any diminishing marginal return is another healthy year. And so to me, at the limit, you should be spending every single dollar towards the health of your society. And so when we look at the US and say, oh, we spend 18% of our GDP, that's a problem. My question is, well, why? We've never used absolute numbers like that as a problem.
- 2:39
- Unidentified speaker (speaker_1): The question is, are we getting what we want from that dollar amount? And that's the whole premise of Jevin's paradox is actually the market size increases as the cost per unit decreases. Now, the cost per unit, the challenge is in the US healthcare system, the reason why it's 18% is because the cost per unit has been rising. We spend probably 50% of our healthcare costs on 5% of people. The US doesn't
- 2:59
- Unidentified speaker (speaker_1): give up on a single person in that way. A lot of people look at the US healthcare system as this great anomaly relative to other healthcare systems. And I'm actually of the belief that the US healthcare system is actually a preview of what's to come for a lot of other countries. You look at the UK, it's just GDP percent of healthcare spent on GDP went from six to twelve. You look at Germany, it went from nine to
- 3:19
- Unidentified speaker (speaker_1): twelve. You look at the US, it went from nine to eighteen. And same thing with our obesity rates. And so to me, again, back to what is more important for society to spend its money on. I couldn't imagine something that's more important than our health, but what we get for it should just be far greater.
- 3:35
- Unidentified speaker (speaker_0): Yeah. So if you ground us in today's reality,
- 3:38
- Unidentified speaker (speaker_1): I'm
- 3:38
- Unidentified speaker (speaker_0): really very curious for your state of the union of the system itself. Yep. And you can picture the obesity rate chart that has, for the first time in a while, kind of flatlined or kicked
- 3:48
- Unidentified speaker (UNKNOWN): the
- 3:48
- Unidentified speaker (speaker_0): other direction.
- 3:48
- Unidentified speaker (UNKNOWN): I
- 3:48
- Unidentified speaker (speaker_0): think GLP one's the primary reason why. Obviously, that's driven your business to an extraordinary degree.
- 3:53
- Unidentified speaker (speaker_1): Yep.
- 3:53
- Unidentified speaker (speaker_0): But give us beyond just that, give us your sort of state of the union. Here's what health is like in the US today.
- 4:00
- Unidentified speaker (speaker_1): Give me a whole podcast by itself. Yeah. It's interesting to
- 4:02
- Unidentified speaker (UNKNOWN): be a good thing.
- 4:03
- Unidentified speaker (speaker_1): think about first where does the money go? Usually, if you want to understand the industry, you just follow the money. So let's say 30 to 35% is about hospital systems, 20 to 25% might be doctor's office, another nine, 10% would be drugs and pharmaceuticals, and then you see the remainder chopped up there. And then a lot of people will talk We'll about, and back to our question a little
- 4:23
- Unidentified speaker (speaker_1): bit around percentage of GDP, the US healthcare system, I would say. is really fantastic, better than people give it credit for at acute care. Yes, it's more expensive, but we have higher cancer survival rates than the NHS. If you get cancer, you wanna get cancer in the US. If you have a heart attack or a stroke, you wanna have it in the US. Our survival rates are higher on average than other
- 4:42
- Unidentified speaker (speaker_1): OECD countries. And we don't use more healthcare than other OECD countries. We have fewer hospital stays. Our hospital stays are shorter. We have slightly more procedures. and scans, which whereas it nets out on a per unit basis, and then our prices are higher, and our administrative burden is much, much, much higher. And then a lot of people will talk about life expectancy in the US. It hasn't
- 5:02
- Unidentified speaker (speaker_1): increased in the last 10, 15 years. But to me, a lot of that is not a reflection of our healthcare system. So there's kind of two buckets of the way we die. Um, the first is like this fast clock, and that will bring down the average uh of the US life expectancy relative to other OECD countries. So that fast clock is like gun deaths, car accidents, overdoses, things like that.
- 5:22
- Unidentified speaker (speaker_1): That'll bring down an average, but it's not the majority of the way we die. The majority we die is with a slow clock, right? Chronic disease. And that has massively been rising, as you mentioned, in the last 20, 30, 40 years. Yeah. So those two things are really the makeup of how illness happens in the US and how people die. And then that's how the money gets spent. As
- 5:41
- Unidentified speaker (speaker_0): you think about the whole thing, what is the most surprising thing that you've come to learn about the system that you think people may not appreciate fully?
- 5:48
- Unidentified speaker (speaker_1): There's probably two things that I would say. One is I do think our healthcare system has one, if not two, but one central flaw from which all other problems stem. And the second is that the entire healthcare system
- 6:03
- Unidentified speaker (speaker_1): is based on time horizons that are almost irrelevant to the individual. So that's, I think, of the surprising thing, which is when you go into the healthcare system, there's a fundamental mismatch of incentives. And if I had to say, what is the problem with our healthcare system? It is that the patient is not the customer. That's the problem that we're trying to solve at Roe. And I think you see it working, but that is the fundamental problem.
- 6:23
- Unidentified speaker (speaker_1): And the reason being is, I mean, you see this in every business that you talk to. whoever controls the flow of money at the point of purchase, that's the customer. That's the stakeholder that everyone builds around. And patients, individuals, we pay for our healthcare. We just are not the customer in the majority of the interactions. So our out-of-pocket expenses, the minority of our expenses. And we pay through our taxes and we
- 6:43
- Unidentified speaker (speaker_1): play through suppressed wages with our employer. And so you then look and say, okay, well where's where is healthcare working? Where does it feel really good?
- 6:51
- Unidentified speaker (speaker_1): And it feels really good where it's cash pay, where the patient is the customer. Do
- 6:56
- Unidentified speaker (UNKNOWN): you
- 6:56
- Unidentified speaker (speaker_0): have a favorite example of that?
- 6:58
- Unidentified speaker (speaker_1): You look at LASIK eye surgery, cost comes down, quality improves, convenience improves. You look at breast augmentation, you look at cosmetic surgeries, costs come down, quality improves, convenience improves. You look at GLP ones, right? Take GLP ones, and they are like this beautiful foil for the rest of the healthcare system. Politicians and regulators have been trying to get transparent prices for
- 7:17
- Unidentified speaker (speaker_1): 20, 25 years. What happens? Pharma goes direct. What happens to the prices? Well, this, as my loving Jewish mother would say, the fakeakta prices of list and you have thirteen hundred dollar drugs that people are paying behind the scenes three, four hundred dollars for. What happens when those go direct to consumer? That list and eck act gets It's entirely limited. When people are pointing fingers between insurance companies and PBMs and
- 7:37
- Unidentified speaker (speaker_1): pharma, and who's to blame? They go direct, you remove the PBM and insurance company entirely. And normally branded drugs every year systematically they go up six, seven, eight percent year over year over year. And so the patent cliff. My hope, and I think you're already starting to see this: more middlemen that do absolutely nothing are getting removed from the process. So they are able to capture the
- 7:57
- Unidentified speaker (speaker_1): same, if not more, gross profit while prices come down. If you look at Lily's earnings, prices come down. volume far outstrips it. And PBMs, to me, they are like the appendix of the healthcare system. At one point in time, they might have served some purpose, but it was so long ago that people can't remember what the heck it was. And turns out when you remove them from the equation, software can do
- 8:17
- Unidentified speaker (speaker_1): exactly what they would have done historically. And so you even see with GLP1s, PBM goes away, insurance company largely goes away. People can debate that and whether or not it should and what they should cover. But for cash pay purposes, PBMs and insurance companies go away, prices go from $1,300 to $149. And the people making the drugs are making more money. And so you can see
- 8:37
- Unidentified speaker (speaker_1): that where it's working, the patient is in control and at the center. And then you usually have people give this criticism. One of the most common is asymmetry of information. And in my mind, it's a little bit similar to like the best form of government. So democracies democracy that work. is the worst form of government, except for all the other ones.
- 8:52
- Unidentified speaker (speaker_0): Yeah.
- 8:53
- Unidentified speaker (speaker_1): In my mind, the patient's the worst person to own their healthcare decisions, except for literally everyone else. And when you go into our healthcare system today, they'll say there's asymmetry of information. You have to sign on the dotted line away anything and everything. And you're not reading that. But imagine you had recourse, which is get to vote with your feet.
- 9:09
- Unidentified speaker (speaker_2): So if
- 9:09
- Unidentified speaker (speaker_1): hypothetically, when we as a society, well, sometimes you have the price transparency laws for hospitals. and people thought that that was this amazing thing, that is epic lipstick on a pig. No industry could survive with its prices not being public. Any company that did that wouldn't get any customers. So rather than us praising that, we should see that as a symptom, where if if
- 9:29
- Unidentified speaker (speaker_1): you hypothetically gave, let's say I don't know what you give your employees for healthcare, Care, what you spend on it, but let's say we spend $20,000 to $25,000 a year per person, if I magically gave them a credit card, that could only be used for healthcare. And let's say $20,000 of it could be used on their healthcare expenses and it would just roll over every year. And then some portion on catastrophic care, which is, I think, the ideal form of
- 9:49
- Unidentified speaker (speaker_1): insurance. But you wouldn't have to make a law that says you have to make prices public. Businesses do that That's to earn a customer's money. And if they don't do that, hey, A, if they don't make the prices public, they won't get the their money. And then if they don't do a good job, they won't get their money. And so one of the reasons why in healthcare there's very little trust
- 10:09
- Unidentified speaker (speaker_1): is because A, there's very, very little transparency and they don't say what they're going to do and then deliver it time and time again. And so where you see people feel that way in healthcare is actually where they're in control in that cash pay environment. Or where insurance is 100% accepted and it covers a hundred. 100% of the cost. And it's basically like they have free money
- 10:29
- Unidentified speaker (speaker_1): and they have choice and foresight. So the idea to me is what we're trying to do at Roe is if we can aggregate patient spend, I think we can bend the healthcare system to the will of patients. I'd
- 10:40
- Unidentified speaker (speaker_0): love to use Roe as just a great example since you know all the data like the back of your hand. Give us a sense of the lineup of products right now. Yeah.
- 10:47
- Unidentified speaker (UNKNOWN): And
- 10:48
- Unidentified speaker (speaker_0): what the pie chart looks like today. What percent are they spending? on each of the major categories?
- 10:52
- Unidentified speaker (speaker_1): Yeah, yeah, yeah. I have to. So we have four main categories. Roe is the leading provider of GLP ones in the country. Cardiometabolic health is a number one category, then sexual health, dermatology, and fertility. And the fastest growing part of the business is GLP1s. And oftentimes people will say, as this has happened, because we've grown over the last four years, we've gone from about a $250 million run rate to over a $3
- 11:12
- Unidentified speaker (speaker_1): million run rate. And we've done that actually with fewer people than. we were in 2012
- 11:16
- Unidentified speaker (UNKNOWN): tunnel shoes.
- 11:17
- Unidentified speaker (speaker_1): But the majority of growth, what's interesting is people will often say, well, those are just weight loss drugs. And that's really both fascinating for me when one, they were approved for diabetes, then they're approved for obesity and overweight, then they're approved for heart disease, then they're approved for sick apnea and liver disease and kidney disease. And they're being studied for neurodegeneration and pain management and addiction and mental health and
- 11:36
- Unidentified speaker (speaker_1): cancer prevention. And so you look and you're saying, yes, the leading part of our business is just treating the leading causes of why humans die on Earth today. That slow clock that we talked about. So I used to be frustrated by that just moniker, and now it's like a badge of honor. It's by far and away the fastest and leading part of our business.
- 11:55
- Unidentified speaker (speaker_0): So I actually would love to spend a few minutes on each of the four driving leading categories, obviously, starting with GLP ones. Why have you been so effective? What has made you the leader? Why don't people just go to these new direct services that the pharma companies have? What is it about Roe that has allowed it to be the place of choice to go get this stuff?
- 12:12
- Unidentified speaker (speaker_1): Yeah. It's a great question because people often ask about competition and differentiation. And so there's a bunch of different ways to talk about it. The first to your point
- 12:19
- Unidentified speaker (UNKNOWN): is
- 12:19
- Unidentified speaker (speaker_1): like the proofs in the play. So Roe is the leading provider of GLP ones owns in the country. We're probably signing up two, three, four, five times as many patients every single day as our competition. So there is clearly some difference. That's
- 12:31
- Unidentified speaker (UNKNOWN): what's gone.
- 12:31
- Unidentified speaker (speaker_1): And so what is that? And then when you think about differentiation, a lot of times people, and I would love if this were the case, want this very specific answer. Like we offer this feature, and someone else doesn't. And the thing is, is if I were to say that right now, I could point to those things and say, well, Roe is the most affordable to start. And Ro Roe has the
- 12:51
- Unidentified speaker (speaker_1): strongest formula. We're integrated with both Novo and Lily. Well, Roe also has cash pay and we help people check their insurance. So we've helped actually over 1% of the US population check their insurance for free, done that entirely with AI. You can get it mailed to your door, you can pick it up in person. We also have worked with our pharma partners to offer multi-month subscriptions where we can actually save patients
- 13:10
- Unidentified speaker (speaker_1): $600 to $1,800 a year. And that's not available in an infinite number of. places. So for many people, the membership actually pays for itself. But the truth is, is that differentiation in my mind, I'm a big believer that the only, only, only source of differentiation is continued innovation. We must be in search constantly of that next checkbox.
- 13:30
- Unidentified speaker (speaker_1): And so we have to invent that next check every single time. Because if we stayed still, if the companies you love stayed still, Apple, Amazon, Google, wherever it may be, if they stay still for six. or 12 months, you see this even in the AI races. Like every four weeks, there's another company being another company. So if you stay still, it's good
- 13:45
- Unidentified speaker (UNKNOWN): for
- 13:45
- Unidentified speaker (speaker_0): consumers.
- 13:45
- Unidentified speaker (speaker_1): It's great for consumers. And so again, that's where I love like the consumers. I love competition, especially in healthcare, because we have to fight every single day to continue to serve. Even when we started the company and the way we built the technology, we built an EMR from scratch. We built our own clear sort of a cap-acredited cap accredited lab. We built our own farm. pharmacies. We built our own pharmacy software. We built our own provider
- 14:05
- Unidentified speaker (speaker_1): network. All of those are seamlessly integrated and they are built in a condition agnostic way. And we had been building this incredible platform for the previous four or five years before GLP1s came out, leaned very, very hard into it, but we were able to quickly expand. And so when people think about us like a condition by condition, they actually should I just think about a world-class care and treatment distribution
- 14:25
- Unidentified speaker (speaker_1): platform that is all virtual. vertically integrated, custom-built software in service of helping that patient achieve their health goals.
- 14:31
- Unidentified speaker (speaker_0): Is there anything interesting to double-click on the options you have for serving something like a GLP one, which is made by a couple of different companies, but not by 50?
- 14:40
- Unidentified speaker (speaker_1): Yeah.
- 14:41
- Unidentified speaker (speaker_0): Is there anything interesting in that dynamic that because there's relatively few suppliers, they you would think would have some sort of power and be able to capture more of the total margin. that's being earned by all companies that are serving a customer GLP one.
- 14:55
- Unidentified speaker (UNKNOWN): I
- 14:55
- Unidentified speaker (speaker_1): think your assumption is right. And by the way, I think that should be the case.
- 14:57
- Unidentified speaker (speaker_0): Yeah.
- 14:58
- Unidentified speaker (speaker_1): I think the inventors of GLP ones should
- 15:00
- Unidentified speaker (speaker_0): earn more.
- 15:01
- Unidentified speaker (speaker_1): Should grab more margin than the people who scale access to debt. I think that's normally what you see for the most part with some demand aggregators. And retail is an okay example here. It's not perfect, but Costco might be another example. where they might have 15% margin on the good itself. They make the majority of their gross profit on a membership,
- 15:21
- Unidentified speaker (speaker_1): but they have an incredibly durable and scalable business. And there's a lot of value for both the suppliers and customers in that instance.
- 15:29
- Unidentified speaker (UNKNOWN): Is
- 15:29
- Unidentified speaker (speaker_0): demand aggregator sort of the Ben Thompson idea? Is that how you think about the business?
- 15:34
- Unidentified speaker (speaker_2): I think so. I'm
- 15:35
- Unidentified speaker (speaker_1): sure he would have a more academic response of why we're not, because it's not zero. marginal cost to serve the marginal person. Yeah. But I think what gives us the reason why pharma comes to us is because we prioritize first and foremost what the patient wants and needs. You've seen other
- 15:55
- Unidentified speaker (speaker_1): companies prioritize in the space, you've seen other companies prioritize their business over patient outcomes, and they are not as large. And so patients come. to us knowing that we will help find for them the right drug, the right treatment, the right dose based on how they prioritize cost quality and convenience, which is what a consumer cares about. I think that's
- 16:15
- Unidentified speaker (speaker_1): why we've been able to integrate with both of the leading pharma companies, is because they know and they want to compete in the marketplace. That is what they would always want to compete in the marketplace over who can best serve patients. across those things. And we facilitate that microcosm of the marketplace.
- 16:31
- Unidentified speaker (speaker_0): What do you think the impact of GLP ones is going to be prospectively? There's been lots written about what it's done so far, the flattening of the obesity curve. The data is all very interesting. But if you think about going forward, as I don't know what percent maybe you could tell us of Americans are on one of these.
- 16:45
- Unidentified speaker (speaker_2): People say 10 to 15 percent.
- 16:47
- Unidentified speaker (UNKNOWN): Yeah,
- 16:47
- Unidentified speaker (speaker_0): it's a big percentage of Americans on the drug. What do you think the percentage of
- 16:50
- Unidentified speaker (UNKNOWN): the drug is?
- 16:50
- Unidentified speaker (speaker_0): perspective story of DLP 1 class drugs will be? So I'm interested both in the broader impact, but also the generations of technology that seem to be. This new one's coming out soon. Seems really fascinating. We welcome your thoughts on that. What's the story from here look like, Debane?
- 17:05
- Unidentified speaker (speaker_1): There's the individual healthcare impact. There's the impact to the healthcare system. And then I think there's the societal impact. On the individual health impact, we talked a little bit about this, but they are upstream of the leading causes of death, what they're approved for: diabetes, obesity, liver disease, kidney disease, sleep apnea, heart disease. They're approved for all of those things already. Four years ago, they were just approved for
- 17:25
- Unidentified speaker (speaker_1): diabetes. So that impact is tremendous. Then there's the healthcare system impact, which we talked about, which is, I think they are fundamentally rewiring the healthcare system. And industries get rewired when large amounts of buyers care about one thing for an extended period of time. So we saw a lot of the healthcare system
- 17:45
- Unidentified speaker (speaker_1): suddenly find out that telemedicine was a good thing during COVID. And what happened during COVID actually, as a specific example, you saw a lot of states relax the regulation that a healthcare provider could treat someone without being licensed in another state. One of the problems of our healthcare system is we have a fundamental supply shortage. We have too many people who need care and too few to provide it. So one
- 18:05
- Unidentified speaker (speaker_1): of the things we were trying to do at Roe is turn a luxury into commodity by turning a service into a product. So when you see that, but COVID ended and suddenly we went back to thinking that when the human body crosses state lines, it's suddenly wildly different. You are going to see GLP1s rewire. They've already started to rewire and ask the questions of well, why does your employer get to decide what is
- 18:25
- Unidentified speaker (speaker_1): covered by your health insurance and have such great influence on your healthcare? Because again, back to incentives in that first problem that we discussed, your employer, they care about you. You care about your employees. I'm sure you do. I deeply, deeply care about our employees, but that is plural. An employer cares about many employees over a shorter time period than their entire life. An individual
- 18:44
- Unidentified speaker (speaker_1): cares about themselves and their family over their entire lifetime. That mismatch in incentives. will naturally create suboptimal outcomes. So, what you're seeing with GLP1s is you are actually seeing the most popular drug of our lifetime or drug class of our lifetime, seeing the most popular drug. The majority of the growth is direct and
- 19:04
- Unidentified speaker (speaker_1): consumer cash pay. Patients are able to vote with their feet. And what happens? All of the things regulators have been dreaming about for a really long time. Prices are transparent, they're coming down, there's more competition, and all of the amazing things. And the third and last one is the societal impact beyond the healthcare system. So if I can go on a little bit of a tangent on this societal one,
- 19:24
- Unidentified speaker (speaker_1): which is the reason we started Roe is very personal to me. And it's, I deeply believe very simply, we help patients achieve their health goals. Because when we do, we think we unlock their full potential. If you do that at scale, you unlock the full potential. of humanity. And I was very, very lucky. I grew up with my dad, who's a doctor, and he saved my life, having a general
- 19:44
- Unidentified speaker (speaker_1): heart condition and a heart procedure when I was 18. But he helped me achieve my health goals to go chase after my life goals. And so he helped me navigate that procedure when I was 18. Right after, actually, the main side effect of my heart medication was erectile dysfunction, which is obviously every 18-year-old scream in their first semester of palates like calling up. hey dad. And he helped
- 20:04
- Unidentified speaker (speaker_1): me navigate that. And I actually I've never shared this publicly, but when I was 12, I didn't grow for about a year. I was already quite small, spoiled a lot. And my parents fought with the healthcare system to get it covered, but to help me get growth hormone. So
- 20:20
- Unidentified speaker (speaker_1): I took an a injection of my leg every single day for about six years. So I entered high school like four. eight, four, nine, and I left like six, six, one. And so those three paths, if you think about it from my perspective, there was either a world where I was dead at 18, 5'3 with erectile dysfunction.
- 20:36
- Unidentified speaker (UNKNOWN): This
- 20:36
- Unidentified speaker (speaker_2): is like not great.
- 20:38
- Unidentified speaker (speaker_1): Or 6'1 and married to the most incredible person in the entire world. And I do think that it was because my parents and my dad were constantly fighting with the healthcare system. They set me on an entirely different trajectory. I had as an individual. On the societal impact, whenever we as a society, whenever we attack the leading causes of death, just
- 20:57
- Unidentified speaker (speaker_1): upstream, not downstream, but upstream when we attack those, you see the shape of society dramatically shift on the other side. So from year zero to 1800, our life expectancy is 30. And a lot of people will say, yeah, it's infant mortality. It's like, yes, it was infant mortality. It's also maternal mortality, it's also infectious disease. Those big free. What ends up happening when we
- 21:17
- Unidentified speaker (speaker_1): largely combat infectious disease and infant mortality and maternal mortality? They're no longer mourning the loss of children and spouses every single day. They invest in the kids that they have. Those kids go to high school, they go to college, women enter the workforce. We have the industrial revolution. Forty percent of the population goes from making food to four. We get electricity from 10% of pounds to 100%.
- 21:37
- Unidentified speaker (speaker_1): And all of that happens. happened, I believe, because health is a precondition to progress. And so right now, if we think of the leading causes of death as the thing I just mentioned, those chronic diseases, if we can attack those upstream, I think we can shift the trajectory of our society
- 21:57
- Unidentified speaker (speaker_1): in ways that we cannot predict, in ways that will be beautiful and amazing and
- 22:02
- Unidentified speaker (UNKNOWN): can't
- 22:02
- Unidentified speaker (speaker_1): wait. to see what happens.
- 22:03
- Unidentified speaker (speaker_0): Do you think that if you had to predict the percent of people on some form of a GLP one 10 years from now or something, what would your prediction be from 10 or 15 today?
- 22:11
- Unidentified speaker (speaker_1): 50 plus percent of people.
- 22:13
- Unidentified speaker (UNKNOWN): You
- 22:13
- Unidentified speaker (speaker_0): think it'll just be a standard whether or not you have the acute versions of the things that were originally on that label?
- 22:19
- Unidentified speaker (speaker_1): Yeah. Absolutely. What's interesting to me is if you think about it, so just pure raw numbers, 75% of the US population has overweight or high obesity. So just based on that, that group is clinically eligible. And then we say, okay, well that's bottoms up. And then what about top down? What percentage of the US population is metabolically healthy? 10, 12%? So they're even interested in
- 22:39
- Unidentified speaker (speaker_1): taking it prophylactically for inflammation or gyroprotective reasons. So he starts to sit here and say, of course, there are some people who should not be on this medication or they might not be able to talk. tolerate it. But as we improve the tolerability and as we better understand a lot of their mechanisms of action, I think what we're seeing is it
- 22:58
- Unidentified speaker (speaker_1): combats a lot of the environmental and genetic impacts that lead to chronic disease in society today. And then there's obviously the massive affordability question. But to me, A, I think the majority of people will be on it. I think satins are a good comp. You see 40, 50 million people on it. And these are much more effective, just the breadth of the label.
- 23:18
- Unidentified speaker (speaker_0): Before we close out this chapter of the State of the Union and the system, I love this notion of jobs over lives as like one framework. Yeah. Talk to us about what you're thinking here.
- 23:26
- Unidentified speaker (speaker_1): Yeah. So there's one of those that might be a little bit more controversial, but we can do it. There's a conversation in healthcare that's happening right now. I also think you see it in other industries where people say things like health. healthcare must remain human. And I think it's the entire wrong question to
- 23:46
- Unidentified speaker (speaker_1): ask ourselves. Not that I don't think parts of it will, but it's an obsession over inputs instead of outcomes. And I think that when you do that, you are not prioritizing patient health outcomes above everything else. And so I think tools, both humans, and new technology, must earn their place.
- 24:06
- Unidentified speaker (speaker_1): And the status quo does not get a pass just because it's of its current existence. And so I think driverless cars are a great example in my mind where we are having quite a bizarre conversation, in my opinion, which is about 40,000 people a year die from car accidents. That is almost the same exact number numbers as the people who die from breast cancer every single year.
- 24:27
- Unidentified speaker (speaker_1): Nuts. Nuts. Absolutely nuts. Drive-less cars in pockets have proven to be 10, 20 times safer than a human driver. So we basically, for certain types of cancer, have a cure. And the conversation is not how do we have operation warp speed for this cure for cancer? It is a lot about and more about
- 24:47
- Unidentified speaker (speaker_1): job displacement. And it's not that I want to diminish job displacement. it's that we should not, and this is what we were talking about, we should not and we cannot prioritize jobs over lots. If we were talking about a cure for cancer and someone said, What about the people currently treating cancer patients without the cure? I don't
- 25:06
- Unidentified speaker (speaker_1): even know that they would be able to. It was the stupidest idea ever. There's a story that I heard a CEO of a driverless car company say. They were speaking to a regulator, and the regulator asked the CEO when they told them about the reduction of deaths. The regulator said, but what about the organs?
- 25:27
- Unidentified speaker (speaker_1): And the CEO was flabbergasted. What the regulator was referring to is the organs from people who are dying in car accidents that can save other people's lives. A beautiful thing, having said that, what the CEO's response was, I don't know whether they said it out loud, but at least when they told me this is what they had in their head, was hopefully they're still in the
- 25:46
- Unidentified speaker (speaker_1): original person.
- 25:47
- Unidentified speaker (speaker_0): Yeah.
- 25:48
- Unidentified speaker (speaker_1): And so I think that we as a society, especially when it comes to health, must prioritize outcomes over inputs. The new thing must prove its worth. So it's not that, hey, technology automatically gets a free pass. It doesn't. It must prove not that it's 1% better, but that is substantially better than the status quo. But we as a result cannot give the status quo a pass. And
- 26:08
- Unidentified speaker (speaker_1): I think we see that with driverless cars right now. And it's a very painful conversation. And I do believe that the people impeding driverless cars where they are proven to be safe should have a body count attached to their name. Truly. And I think we will look back on it as such. And I think that one of my biggest worries is related to healthcare.
- 26:27
- Unidentified speaker (speaker_1): that we will have that same level of prioritizing inputs over outcomes. There
- 26:33
- Unidentified speaker (speaker_0): was that great chart a couple days ago showing the total revenue of GLP ones versus AI revenue. And
- 26:38
- Unidentified speaker (UNKNOWN): the
- 26:38
- Unidentified speaker (speaker_0): GLP ones are bigger.
- 26:39
- Unidentified speaker (speaker_1): That's right.
- 26:39
- Unidentified speaker (speaker_0): It's kind of crazy.
- 26:40
- Unidentified speaker (speaker_1): There's two cool things here. One is not only were GLP ones larger from a revenue perspective, but individuals pay for GLP ones twice the number of people pay for GLP ones. than pay for AI. Yeah. So from a consumer's perspective, I think they're telling you, I think that is a problem with the AI narrative right now that there's not enough of a consumer
- 27:00
- Unidentified speaker (speaker_1): impact day-to-day. So the gap of real-time impact to the tens or hundreds of millions of people hopefully can be bridged.
- 27:09
- Unidentified speaker (speaker_0): Vanta automates compliance so your team can spend less time on security reviews and more time getting customers. Vanta cuts audit prep by 82% and gives you instant, up-to-date proof of trust without all the manual work, so you can close deals faster and with less friction. Customers report a 526% return on investment, and
- 27:29
- Unidentified speaker (speaker_0): more than 16,000 companies use Vanta, including Ramp, Harvey, and Snowflake. Get started with $1,000 off at vanta.com/slash invest.
- 27:39
- Unidentified speaker (speaker_0): Ridgeline is the first end-to-end system of record with embedded AI for investment management firms running portfolio accounting, reconciliation, reporting, trading, and compliance on one unified platform. Firms are moving off legacy technology and onto Ridgeline because of how far ahead Ridgeline's AI features are compared to anything else in investment management
- 27:58
- Unidentified speaker (speaker_0): software. I've been hearing from a lot of investment managers about AI, and they fall roughly into two camps, with some unsure where to even start, and others convinced that they can build their own order management system over a weekend. The reality is that running an investment firm will always require governance, controls, and a single source of truth for your data. And no amount of AI enthusiasm
- 28:18
- Unidentified speaker (speaker_0): changes that requirement. Ridgeline is built on exactly that foundation, which is why I believe that the firms that come out ahead in the AI era will be the ones running on Ridgeline. Ridgeline's unified platform. If you're serious about your firm's AI strategy, Ridgeline should be part of that conversation. And you can request a demo at ridgeline.ai.
- 28:37
- Unidentified speaker (UNKNOWN): I'd
- 28:37
- Unidentified speaker (speaker_0): love to know how to tell the story about this crazy company turnaround that you've been through. Company's been around nine years. And about four or five years ago, you went through a really fascinating period of time. And you said the number casually earlier. but the company's like 10 times the size it was not that long ago. Obviously, GLP one's is a big part of that. And the
- 28:57
- Unidentified speaker (speaker_0): company's charts look kind of like the GLP one's charts. So that's one explanatory factor. But that hides a very fascinating story that I'd love you to tell in some detail because when I've heard it from you in the past, I just think it's such a cool, fun example.
- 29:12
- Unidentified speaker (UNKNOWN): And
- 29:12
- Unidentified speaker (speaker_0): I think you're willing to be raw about the details of it. for what entrepreneurship is like. Like,
- 29:16
- Unidentified speaker (UNKNOWN): oh,
- 29:17
- Unidentified speaker (speaker_0): cool, three billion bucks, that's a great business. Yeah. Nine years and a lot of blood, sweat, and tears to get here. So yeah, maybe tell show this very interesting history of it.
- 29:24
- Unidentified speaker (speaker_1): Cool in retrospect, quite painful during it. But I agree with you. Get started, I would say the moment I knew we needed to reset. So we did refound the company in the summer of 2022. But the moment we decided we needed to reset.
- 29:39
- Unidentified speaker (speaker_1): was December 2021. I am on a plane, headed to visit my parents, and I'm looking at my laptop and I'm looking at the previous year's performance. Now, mind you, 11 months prior in January, we had raised $500 million at a $5 billion valuation. And we did almost every textbook mistake in the book. We confused our
- 29:59
- Unidentified speaker (speaker_1): long-term vision with our near-term strategy, and we decided to do everything and hire everyone. and try to do everything all at once. And that was a disaster. And I realized that. People are like, oh, how did you not realize that? As it was going, well, sometimes looking at quarterly results or annual results or good moments of reflection, it hit me like a ton of bricks, actually. So I'm on the plane, I'm looking at this, and we had grown 9%
- 30:19
- Unidentified speaker (speaker_1): in 2021. We had hundreds of millions of dollars in the bank. And we were burning, but we were what I would call a zombie company. which is like you're not growing fast enough to get out of it, but you're not burning where you're gonna die. So you are just a zombie walking around. And we had a pref stack that could squash an elephant. It was like an $800 million prep stack. So I'm sitting there having worked 70, 80 hours a week. Our
- 30:39
- Unidentified speaker (speaker_1): team had for years, for years, for five years. And our team had devoted themselves so much to our mission, and we might not even clear our press pref stack. So it was a tough plane ride. As this is happening, at the exact same time, our people team had sent out a wonderful Christmas gift to every employee at the company. And mind you,
- 30:59
- Unidentified speaker (speaker_1): it's 2021. We are trying to do everything right. This is a local New York City women's owned business that made macaroons, and it was beautifully packaged in this plastic package. And I see at that moment, flying home for Christmas, I see a comment in the general. channel of Slack and sends a message to the whole company. And someone said, At here, next
- 31:19
- Unidentified speaker (speaker_1): time we send out Christmas gifts, can we not do it in an ocean full of plastic? And I was like, I had steam coming out of my ears. I wanted to reply, add here, you're fired. And I was so frustrated. Thank God for honestly I had Wi-Fi on the plane. Because I didn't send a message, just looked at it. And my first realization though was bad. but my second one was
- 31:39
- Unidentified speaker (speaker_1): way worse. The first one was I was frustrated with this person. The second one was I was even more frustrated with myself. Because no one gives a shit about the packaging when you are winning as a company. We were literally and figuratively, we were macaroon soft. We were a soft company. It's not how I was raised, it's not how we wanted to build, it's not On our company culture, it was terrible. And so I
- 31:59
- Unidentified speaker (speaker_1): shifted from looking at our financial results to I wrote a six-page six page memo. to my co-founders. And the moral of this memo was basically I deeply believe in our mission and vision. We have built an incredible technology platform and we have absolutely amazing people here. So I believe in the bones and I believe we can fulfill our mission. But here are the things that are wrong. And the single
- 32:19
- Unidentified speaker (speaker_1): best way that I know how to fix it is by fully embracing a strong attract and strong repel culture. If we have that with great people, with our technology platform, we clearly have the resources. I think we can go put a dent in the universe. If you disagree, we need to have this conversation. If you agree, then starting in 2022, I'm gonna go rip some band-aids. Fortunately, they agreed. Then
- 32:39
- Unidentified speaker (speaker_1): January 2022 happens. We move on from about seven VPs from January to May. And then May to June, we move on from about 20% of the organization. Now, quickly, because I feel obligated to say this. which is I think Silicon Valley has this odd, almost fetish with layoff. I think they reward it too much, if that makes sense. When it happens, people
- 32:59
- Unidentified speaker (speaker_1): are cheering it on. And I think for me at least, it would have been A, a lot more efficient to have never done that in the first place. Second, it's the absolute worst part of the job to take someone's livelihood away. And the second, it's not, I don't like that person very much.
- 33:14
- Unidentified speaker (UNKNOWN): And
- 33:14
- Unidentified speaker (speaker_1): the third thing is I talked about we parted ways with VPs in 20% of the organization, but I'm a big believer, back to the strong track, strong rappel, that I do believe in it's not in a cheesy way that there's a fit component. It's not just is this person talented or is this person smart or not? I had an internship my junior year of college at Booze. There were 12 interns and 11 eleven
- 33:34
- Unidentified speaker (speaker_1): of them got jobs and I got fired four weeks into the internship. I didn't even know that was possible to get fired from a consulting internship. But I did. Four weeks in, I was consulting for the yellow pages. I got fired and I got put on the beach and asked to do paperwork. And then seven weeks in they asked me to leave. So I do believe that you can have people who are talented, but just not be in the right environment. So we move on
- 33:54
- Unidentified speaker (speaker_1): from twenty percent of the organization. Then my co founder Co-founder Rob at the time, there were three of us, co Co-founder founder Rob, he passed the baton for the next leg of the relays. relay race. So it was me and Simon. And I give him a tremendous amount of credit for doing that and recognizing that. I mean, he's still on the board, we're still close. And then we re-founded the company, which had several components to it, which we doubled
- 34:14
- Unidentified speaker (speaker_1): down on top talent, we put everything under the row brand. So we were Roman, we extended beyond men's health. We dropped the man, we put all of our different brands under row, one brand. We massively updated our ways of working, which involved rolling out new principles, one of which was actually when Solicites say work hard. And when we were even rolling out that principle,
- 34:34
- Unidentified speaker (speaker_1): people were like, Do you mean care deeply? And I was like, that's another principle. I explicitly mean work hard, not ambiguous. And then we said, here's our new strong attract, strong repel culture. And we were very explicit. We said, look, we take full, full responsibility for not being clear about not just the
- 34:54
- Unidentified speaker (speaker_1): what we are building, but how we are building it. So a strong attract, strong rappel culture in my mind, the best products, the best music, the best fashion, the best media, strong attract, strong rappel. The same reasons why you might love something or the same reasons why someone else might hate it doesn't make them a better or worse person. And the best analogy in my mind is like a restaurant. Steakhouse, don't go to a steakhouse if you're a vegan and don't go to a
- 35:13
- Unidentified speaker (speaker_1): vegetarian restaurant if you're a carnage. carnivore. And it doesn't mean, by the way, that Roe is beyond feedback. We love feedback. We are just very explicit where if you were to give me feedback at Roe, I would tell you is this a feature or a bug? Try to eliminate bugs. We double down on features. So you should not go into a steakhouse and say, hey, this steak, replace it with a mushroom. You should say,
- 35:33
- Unidentified speaker (speaker_1): that's a feature, not a bug. The fact that it's meat. But if you were like, hey, I ordered medium rare and it's actually well done, that's a bug. So if someone tells me they don't have enough context to do their job, that's a bug. So fully embracing a stronger track, stronger appel culture and making the menu of that restaurant very, very clear to earn the right for again, where people work is a
- 35:53
- Unidentified speaker (speaker_1): gift. They spend the majority of their waking hours there. And so to me, that was essential in creating that track, strong apell appel culture, which is basically if I had to distill it, it's extremely heterogeneous backgrounds and expertise, but a homogenous way of working. We work one way at row. Our what, why, how is very, very clear. We explicitly articulated that
- 36:13
- Unidentified speaker (speaker_1): and then said, opt in or opt out to this. Another six, seven percent of people opted out. And now we're at September, October 2022, and we have grown 100% basically year over the year for the last four years. We're We 600 people. when I was on that plane. We're now 400 and change. And we've 10x the business. So we've 10x the business with
- 36:33
- Unidentified speaker (speaker_1): 30% fewer people.
- 36:35
- Unidentified speaker (speaker_0): I'm curious to what you would attribute having gone soft as a business prior to that refounding moment. Yeah. As advice to others out there, like don't do these things. This is what got us in trouble. I'm curious about that as well.
- 36:46
- Unidentified speaker (speaker_1): The first hundred people we hired, 95 of them we had known or worked with before. So our culture was just through osmosis. And if I had to distill our culture, it's very much extremely high performance and big heart. And they're not balanced. They are both to a lead. So if you come and you have a big heart and you are not performance and metrics driven, you
- 37:06
- Unidentified speaker (speaker_1): are gonna think that I'm a jerk. If you are extremely performance driven and you do not have a big heart, you're gonna find a lot of what we do probably sappy. and cheesy and why are we spending time talking about this? But it's that rare duality of both turned to 11. And I
- 37:19
- Unidentified speaker (UNKNOWN): think
- 37:19
- Unidentified speaker (speaker_1): as honestly, it's how it was raised. That was the culture of how it started. And then we were not explicit about that, though. So we were kind of like a restaurant that said, come here when you're hungry, we serve food, and then gave you the menu. The best advice that I would have to founders is the best company cultures, I believe, are strong attract, strong repel. It knows who it is and it can. continues to
- 37:39
- Unidentified speaker (speaker_1): try and double down on the features and eliminate the bugs. But you have to articulate what that is so that you know what it is and everyone else knows what it is and be unrelenting in protecting it. So I think the biggest reason is my co founders and I let it get away from us because we candidly let other people, too much of other people, determine what that was. But we also, again, these were very good people coming into the
- 37:59
- Unidentified speaker (speaker_1): company, but we owed it to them to be far more explicit about the menu than we were. So I would take full responsibility for that. And I think founders do have to. I think the biggest thing that was the turning point is I was never going to quit. And so the second you realize as a founder you're never quitting, then you do have to make it a place that you absolutely love to work. And you are going to be the
- 38:19
- Unidentified speaker (speaker_1): only person. I think you and your co-founders are going to be only people that can truly, truly create that. And so that's what I would say to protect that genre strong and charge.
- 38:26
- Unidentified speaker (UNKNOWN): So
- 38:26
- Unidentified speaker (speaker_0): back to this idea. of okay, 10X with two-thirds of the people, how much of that is tailwind? How much of that is efficiency of the work of the people that's because of technology?
- 38:36
- Unidentified speaker (speaker_1): It's a lot of both. You do not see this level of growth over this time period without riding also a massive wave. But there's a reason why there's one company that's the leading provider of GLP1 GLP1s in the country by a sizable sizeable margin. If you look at credit card data, we'll probably signing up two. three times second, third, fourth, fifth place. So I think that we are riding
- 38:56
- Unidentified speaker (speaker_1): in the same way others are a generational tailwind, but we're doing it better than anyone else. And I think the same thing you compared earlier GLP1s to AI, and you'll look at Novo and Lily to OpenAI and Anthropic. Like There are many companies other than OpenAI and Anthropic that have the same tailwind that didn't ride it to the same extent.
- 39:14
- Unidentified speaker (speaker_0): Yeah.
- 39:15
- Unidentified speaker (speaker_1): Anthropic is I don't know how many years old. So you do have to have that wave. But like no different, you can probably tell by now I love analogies, but like no different than surfing, you have to catch it. And it's really hard to catch a tsunami. Other people let it ride right under them or crash on top.
- 39:30
- Unidentified speaker (speaker_0): What are the other underrated ways that you've done that?
- 39:32
- Unidentified speaker (speaker_1): First and foremost, I think you can build anything if you have the best towel. talent. So we doubled down on our top talent from a compensation perspective.
- 39:39
- Unidentified speaker (speaker_1): from an equity perspective, from a coaching and resourcing perspective, constantly investing in the best people. And I think if you look at that 400 people that are at row, we started with 600 and change and whittled it down. And I deeply believe that our team is the best in the industry. That's first and foremost, because when you have an incredible team, you have a strong attraction on our repel po
- 39:59
- Unidentified speaker (speaker_1): culture. And then you also, one of the other things is ridiculous. levels of focus. We leaned into sequential nature of building things versus parallel. And Johnny I talks about this and Frank Slootman talks about this. But you actually get way more done than you think when you build things sequentially versus in parallel. There's an impulse to
- 40:19
- Unidentified speaker (speaker_1): build things in parallel because you see more progress across each thing over a shorter time period. So you almost have to be patient because. if you're there over the first, let's say over a 90 day time horizon, if I want to build five things, I could push a little bit of each one. And 90 days later, I'm going to see more progress across all the things that I want to do. But if I just pushed on one of them,
- 40:39
- Unidentified speaker (speaker_1): that one thing will be much, much farther and will have a much greater impact. And the analogy that I might give is it's kind of like only working on the first 10 years of a compound interest curve and never. getting to year 30. That sucks. You lose all of the benefit. But if instead you have ridiculous levels of focus and you do things sequentially, and the thing that you were doing
- 40:59
- Unidentified speaker (speaker_1): next builds on the first thing. And so we leaned heavily into sequential versus parallel. And that is one of the things, that ridiculous level of focus is one of the things. And the entire company, there was very little context switching. And it started actually because I didn't feel that we were moving fast. enough in December like 2022. Just after this, we had launched our beta
- 41:19
- Unidentified speaker (speaker_1): program and I started a daily steer meeting at 850 in the morning with our entire leadership team. And we met every single day at 850 for two straight years. Could it be 10 minutes, could be 15 minutes, could be five minutes, could be an hour and a half until everything that we needed to do that we needed to align on and decisions that need to be made were made. And what ends up happening is for that, for example. it was
- 41:39
- Unidentified speaker (speaker_1): very difficult where if you and I are talking and it's Monday at 850 and it's like, great, you're owning this next step. You can't show up on Tuesday without having pushed that thing forward. And then you definitely can't show up on Wednesday without having pushed things hard. But if instead, if we meet on Monday, we don't meet Monday through Friday, but we just meet on the following Monday, so many other things come up
- 41:59
- Unidentified speaker (speaker_1): where oh, I got sought track with this, and this was important. I didn't know which was there was a stack ranking. Oh, this came. You cannot do that within a 24-hour time period. So the speed of the organization, the alignment just was second to none. And we will do that consistently when we need to put a jetpack on certain teams or initiatives. But there was a bunch of other things. The other thing that I think we did is we killed long-term roadmaps. And it's
- 42:19
- Unidentified speaker (speaker_1): quite painful for people when I tell them that they think we're crazy. I wouldn't advocate this for every company. And my push to people when they read that or when I say, that is that don't miss the forest for the trees. It's not that nothing we did at the organization would be planned past six months. And it's not an excuse for a lack of rigor. It's actually that in an era like the one we are in right now, where both
- 42:39
- Unidentified speaker (speaker_1): GLP1s and AI, that industry is changing so rapidly. Spending a lot of time on long-term roadmaps is like printing out map quests instead of using Google Maps. It is false precision. It's a giant waste of time. Any new piece of thing that changes the course, steps three through 17 are immediately irrelevant. And you've just wasted a ton of time.
- 42:59
- Unidentified speaker (speaker_1): And you will have a much better idea of what step three to four should be once you've done one, two, and three. And so I think doing that, we got very good as an organization of living with longer-term Longer term uncertainty, but short-term precision and rigor. And I think it's kind of similar to your concept. I don't want to put words in your mouth, but it's kind of similar to your concept of
- 43:18
- Unidentified speaker (speaker_1): avoiding being overly goal-oriented. It's that same thing, which is our long-term goals and vision is very, very high level and simple and unchanging. We help patients achieve their health goals. When we do, we unlock the full potential of a human. We do that at scale, we unlock the full potential of humanity. How we do that in the short term and
- 43:39
- Unidentified speaker (speaker_1): day to day, we can respond to the data that we see. We can respond to what patients tell us. We can respond to new inventions of new treatments, a regulatory change, whatever it may be. AI coming. So it allows you to, I think, be cheesy phrase but stubborn on the vision, flexible in the details.
- 43:52
- Unidentified speaker (speaker_0): Yeah. Speculate a little bit on where you think we go next as a healthcare system in the US. There's all these amazing companies discovering drugs using AI. I'm sure the medicines that help you. achieve your mission for your customer are gonna proliferate like crazy. Just speculate on where you think things are going, what has you excited, what has you worried?
- 44:11
- Unidentified speaker (speaker_1): I think we are at the beginning of this patient revolution. I do do believe that, partially because of the systemic failure that is happening. Like you talk about tailwinds. There's the GLP1 tailwind, but I actually think there's three tailwinds to our business. The first is that human biology. is coming online. So that's everything from self-reported symptoms to
- 44:31
- Unidentified speaker (speaker_1): your lab tests, to your genetics, to your wearable data, but your biology is coming online. So number one tailwind, biology coming online. Number two, what used to require a specialist now requires a prompt. When we first started, people would ask us questions like: what type of doctor am I going to get online? First, they dramatically underestimated how
- 44:51
- Unidentified speaker (speaker_1): how flawed the existing healthcare system was and how many doctors were burnt out and fed up and needed an alternative way of life. So we have really high-quality doctors who get to work from home and see their kids in the same way that we see that today in tech. But I think what's interesting is to see investor sentiment change where they're paying 100K a year for a concierge doctor and they ping Claude for 20 bucks a month, and it's way better.
- 45:11
- Unidentified speaker (speaker_1): So used to require a specialist, now it requires a prompt. Third is there are now treatments that do radically shift the quality and quantity of people's lives. They're just not evenly distributed. Some people live in the future, it's just not even distributed, kind of thing. And we think about Roe being the largest provider of GLP1s in the country. Some of the questions that we start to ask ourselves
- 45:31
- Unidentified speaker (speaker_1): is okay, well, why do men lose less than women where our RGLP GLP wants? ones? Why do people of Hispanic descent lose less than Caucasian people? Why do some people lose 35% of their body weight and other people lose live? Why do some people experience side effects and others don't? You add on genetic data, you add on wearable data, you add on ongoing lab tests, you add on self-reported data. So you add on all of these. And the question that you constantly
- 45:51
- Unidentified speaker (speaker_1): ask yourself back with medicine being trial and error is: can you get up the faintest footsteps of a disease? Just like a whisper. Because if you can do that, that's where you can really shift the trajectory. So those three tailwinds. of biology coming online, AI, what used to require a specialist, now requires a prompt, and current and new treatments that both leverage
- 46:11
- Unidentified speaker (speaker_1): that, but then allow you to actually turn the service of concierge care into a commodity anyone can access, that can create that patient revolution. And I think we can go even further than that. Not just concierge care online, but I think we can get a whole new form of healthcare for the price of. Netflix.
- 46:27
- Unidentified speaker (speaker_0): I think you're on a GOP one. I
- 46:29
- Unidentified speaker (UNKNOWN): am
- 46:29
- Unidentified speaker (speaker_1): on a GOP one, yeah.
- 46:30
- Unidentified speaker (speaker_0): So what is your pitch to the person? Actually, pitch me. I'm not on a GOP one. I don't think I traditionally would have been the form factor of a person that would be on one.
- 46:39
- Unidentified speaker (UNKNOWN): Yeah.
- 46:39
- Unidentified speaker (speaker_0): How would you pitch people, I mean the general populace that are curious about this technology, let's call it this method?
- 46:47
- Unidentified speaker (speaker_2): So I'm
- 46:47
- Unidentified speaker (speaker_1): I'm on several different trucks. drugs. I'm a big believer in all of the things. diet, exercise, sleep, drugs and supplements, community. Those are basically the five things you can do for your health. So back to that incentive structure, which is first, the time horizon that I am looking to reduce risk for myself is radically different than the typical healthcare system is
- 47:07
- Unidentified speaker (speaker_1): measuring risk. They're measuring risks on 10, 15 year time horizons. I think I'm pretty confident I'm gonna going to be good when I'm 45. I'm worried about 55, 65, 75. And a lot of chronic disease are area under the curve problems. How long do you spend at elevated LDL levels? Or how long do you spend with metabolic dysfunction or insulin resistance? So they're area under
- 47:27
- Unidentified speaker (speaker_1): the curve problems. As far as the pitch that I would make to you, I wouldn't say you must be on a tail promoting shouldn't. There would be first, what are your health goals? Then you would say, what are some family history trying to understand? And then also your risk tolerance, your risks and benefits. And then ultimately, you're going to have to ideally you work with a provider to understand what combination
- 47:47
- Unidentified speaker (speaker_1): of treatments might be right for you. And I don't give that answer of hey, work with a healthcare provider, see what maybe for you. Sounds like an ad at the end of it. But it's actually because that's truly how it should function. My quote unquote health stack has been built up over the last 10, 15 years with my dad, ABT. A B testing different drugs, adding them on top of each other, taking some off, adding others on,
- 48:07
- Unidentified speaker (speaker_1): measuring my blood test values and other metrics along the way to dial in for me based working backwards for my health goals. My dad had his first heart attack and stroke when he was actually 39, had to stop practicing medicine. And there's sort of blessing and a burden about that, which is he got the thing that he loved the most taken away from him at that time. But
- 48:27
- Unidentified speaker (speaker_1): he also became a stay-at-home dad and I got to spend a lot of time with him. And in many ways, I'm sure a therapist would have a lot to say about this, but in many ways, I feel like I'm trying to recreate him with software. I'm trying to give him to everyone, keep him alive forever in some way, shape, or form. But as a result, I've been very aggressive when it comes to heart disease. So my cholesterol when I
- 48:47
- Unidentified speaker (speaker_1): was 30 years old was 230. My Apo B was 100. plus, my LDL was 130, 140. And I was eating and exercising and doing all the things that are in your control, but my genetics were such that I needed additional support. And so I started statin, then I started Zetios, brand new for
- 49:06
- Unidentified speaker (speaker_1): Zetomide, then I added Rapatha, which we've talked about, and then I added a GLP1. GLP one. And my LDL went from 130. to 70 to 80 to 60 to 10. My Abo B went from 90 to 60 to when I skip my APO B, I have a less than in front of it. There's like a search party out for my Apo
- 49:26
- Unidentified speaker (speaker_1): B. I'm very proud.
- 49:28
- Unidentified speaker (speaker_1): So I'm willing to be disproportionately aggressive here relative to maybe the population. And so that to me would be the conversation that you would ideally have. Yeah. And so we go from there saying, what's really important to you? What are you trying to achieve? What are your risks? And then you'd analyze the risks and benefits of each decision.
- 49:45
- Unidentified speaker (speaker_0): So for that one, as an example, I'm fascinated by the LDL thing and the area under the curve. I have no history of heart disease in my family, luckily, but I take her path because my LDL is really high. And so you and others have convinced me of the merits of this, along with great doctors, et cetera. But something like that, let's just stick with that example in case Okay, you're on so several things to bring it from 130 to
- 50:05
- Unidentified speaker (speaker_0): 10. What are the trade-offs in your mind associated with that specifically? And how do you think about what the benefit is? Yep. Probably years of life or quality of life, but how much? And then what the costs are or the risks are associated with that.
- 50:17
- Unidentified speaker (UNKNOWN): Yep.
- 50:17
- Unidentified speaker (speaker_2): So with any one of them, they have risks
- 50:19
- Unidentified speaker (speaker_1): and benefits. And I've actually dialed in the dose to where I don't experience day-to-day side effects from any of the
- 50:24
- Unidentified speaker (UNKNOWN): one of those.
- 50:24
- Unidentified speaker (speaker_1): But I have tried where up when I started with a statin, and I first asked myself, should I increase the dose of my satin? Should I add Zetia? Should I add Rapatha? And so I dialed in each one of those things independently, went off some, went on some to see the marginal impact of each one, as well as to make sure I could isolate if I were experiencing side
- 50:44
- Unidentified speaker (speaker_1): effects. Was it dose related? Was it drug related? Was it potentially a combination of certain treatments? And so was I able to find the response. regimen with my doctor to be able to navigate that. So with anything, the downside is really costs and side effects. And then I think about it, which is interesting to me, which is the asymmetric downside of getting a heart
- 51:04
- Unidentified speaker (speaker_1): attack or a stroke for me. To me, when I think about it, I take these medications, they're remarkably safe. The Stock side effect profile for me is incredibly favorable. And it's a couple hundred dollars a month. And that is worth decreasing my risk of heart disease by literally whatever percentage it ends up doing.
- 51:20
- Unidentified speaker (speaker_0): Yeah.
- 51:21
- Unidentified speaker (speaker_1): That might not be the case for everyone, but I actually think you're going to see like Repatha is a great example of where I hope you're going to see one prices come down. What happened when it went direct? Went from six hundred dollars a month to 200. Went down 60, 70%, and hopefully it gets lower. There's a new oral coming out. an oral PCSK9. It's actually an oral peptide
- 51:41
- Unidentified speaker (speaker_1): PCSK9. And the way that that was discovered, and I think this is a great example of where AI can be tremendously helpful from a healthcare perspective. So where AI is really, really good, as we all know, it's where there's a ton of structured data when there's a verifiable reward and there's really tight feedback loop. That's where math and coding really thrive. Comic medicine is
- 52:01
- Unidentified speaker (speaker_1): it's trial and error. A lot of the data's data on is unstructured, and the feedback loop up death or heart disease takes a really long time. And so the PCSK9 is sort of a beautiful example of can we do a more of that and can we do it faster? So there's a Dallas heart study, the year 2000. They
- 52:15
- Unidentified speaker (UNKNOWN): had
- 52:15
- Unidentified speaker (speaker_1): about 3,500 patients, half black, half white. Those patients get genetic testing, they get scans, they get imaging, and they get cared for on an ongoing basis. 2006, the researchers realized so six years later, the research. researchers realized that it turns out there's a group of people in this study that have a faulty PCSK9 gene and they have basically LDL levels in the
- 52:35
- Unidentified speaker (speaker_1): 30s to 40s. And they have a 85 to 90% risk reduction of heart disease, no matter what they did. Drink, smoke, cheeseburgers, whatever. They were not dying of heart heart's disease. They could die of anything else, basically, except for heart's disease. From 2006, 2015, to you have Angen invent Repatha, a bi-weekly injection. Now you have others that are up every month, every six
- 52:55
- Unidentified speaker (speaker_1): months. Now you have Merck invents an oral peptide this year that got approved, and it's an oral PCSK9. From year 2000 to 2026, almost a quarter of a century, to invent an oral version that mimics that quote unquote faulty gene, but that, if taken early enough, might largely prevent. and
- 53:15
- Unidentified speaker (speaker_1): eliminate the leading cause of death in the US. That's unbelievable. But it took us six years from genetic testing to discovering this faulty gene. Six percent of a century, twenty-six percent of a century to get it out. That's too long. Think about the number of lives that could be saved. It's not to be too cheesy or sappy, but it's kind of similar to your question around what's the kindest thing
- 53:35
- Unidentified speaker (speaker_1): anyone's ever done for you. When I heard your answer to that question, it was beautiful.
- 53:39
- Unidentified speaker (speaker_1): and powerful. And you said the reason I care about it so deeply is these little acts of kindness can shift the trajectory of someone's life. And the question is, can you do the same thing with health where it's just a little small nudge in the very beginning of an illness? And I think you can. I think we can start to do that. I think we're on the cusp of another
- 53:59
- Unidentified speaker (speaker_1): shift of that zero to 1800 eighteen hundred where life expectancy was 30. For the last 70 years, we went from 71 to 79. How do we have that next big inflection? I think we can get there.
- 54:09
- Unidentified speaker (speaker_0): Seems like the right time to ask more about this comment you made that you're trying to recreate your dad and software. Yeah. Say more about that.
- 54:15
- Unidentified speaker (speaker_1): I think he's changed my life in so many different ways. It's hard to I've never been asked the follow-up question on that. And it's hard to put into words the impact that I think he's had on my life. and how much he inspires me. But I try.
- 54:30
- Unidentified speaker (UNKNOWN): I
- 54:30
- Unidentified speaker (speaker_1): guess at my core, I do believe that the best way that I can have a positive impact on the world is to give people more healthy, happy years. And if you can do that, then they can chase their life goals. And I guess I grew up around someone in my dad who devoted his
- 54:50
- Unidentified speaker (speaker_1): entire life, every second of every day. That man is just trying to give additional healthy years to people because I think that's who he thinks, and I believe this to be the case. That's who he was born to be. And I've seen up close in person the impact that that's had
- 55:10
- Unidentified speaker (speaker_1): on myself and loved ones. And I love the written words. word and I love technology because it is an incredible form of leverage. I'm still reading books that were written 2,000 years ago. And technology obviously scales a small group of people can have a tremendous impact on the world. And so I saw the impact that my dad had on the loved ones myself
- 55:30
- Unidentified speaker (speaker_1): around us, but he was limited by those he could speak to directly or those whose hands he could hold. And so if
- 55:40
- Unidentified speaker (speaker_1): I can recreate that with software and operations and technology and give that to other people, it would be hard for me to think about a life better spent than trying to do what he did for many, many people for millions of people.
- 55:55
- Unidentified speaker (UNKNOWN): Do
- 55:55
- Unidentified speaker (speaker_0): you say more about this idea of the thing you were born to do as a notion, what you've observed in others that seem to have found that thing why you believe that that's a thing in the first place, what it's like being in that versus not sure at points of your life you weren't in that state. Anything else you could share about that idea?
- 56:12
- Unidentified speaker (speaker_1): I think a lot of stories make more sense in retrospect than during. I don't know that when I was younger I felt that I was born to do what I'm doing today. But when I look back and see how I got here, it makes perfect sense to me. And I think the same thing actually about my wife, too. She runs a YouTube channel.
- 56:32
- Unidentified speaker (speaker_1): Actually, after everyone here has fully watched all of Invest Like the Best, every single one. And you're looking for something else to watch. She runs a YouTube channel called Huge If True.
- 56:41
- Unidentified speaker (speaker_0): Not just a YouTube channel, like one of the best and biggest ones.
- 56:44
- Unidentified speaker (speaker_1): I would actually argue that she's the best journalist on the internet.
- 56:48
- Unidentified speaker (speaker_0): She's very good.
- 56:48
- Unidentified speaker (speaker_1): She's very, very good. She's definitely my better hat. half. But the incredible thing is when she talks through why she does it, she will say, When people see a better future, they help build it. And people will ask her all the time. They'll say, How did you get into this? Why do you love to explain things to people? And she said, She's only realized this in retrospect
- 57:08
- Unidentified speaker (speaker_1): that I think she was born to do the thing that she's doing today. Which is she grew up, her two parents were lawyers. And her dad was a corporate litigator, but also did pro bono death penalty cases. And both of their parents would talk about them at the dinner table with Cleo when she was a little girl, nine, 10, 11, 12, death penalty cases. But he would
- 57:28
- Unidentified speaker (speaker_1): obsess over opening arguments, closing arguments, and every little phrase. And what she saw though was if you could explain something to a group of people, to 12 people of your peers. if you could explain something to them where they understood something new about the world, that you could change the trajectory of someone's life. And that is why her dad was so passionate about what he did.
- 57:48
- Unidentified speaker (speaker_1): And so she grew up in a household understanding that education and educating people in a powerful, simple way can change the future. And so she now to this day wakes up and gets to try and do that at scale. And I think only as we've talked about, because we both are founders, and I think look back
- 58:08
- Unidentified speaker (speaker_1): and say, well, it kind of makes sense how we ended up here. But it was less intentional than this is what we were meant to do.
- 58:15
- Unidentified speaker (speaker_0): Maybe even pitch a little more like what the benefits are when you find that thing, how it feels to be doing the thing.
- 58:22
- Unidentified speaker (speaker_1): Oh, it's such a gift. You don't feel like you're working. It's so energizing. I skip to work every single day. My team at this point knows on Friday never say, have a good weekend because I will respond. I can't wait till Monday. I think there's no greater gift than working with other people to have a positive impact on the world. And so when you find
- 58:42
- Unidentified speaker (speaker_1): that, of course, there's personal and professional life, but when you find harmony between those two things and you don't feel like you are quote unquote working, it's like a design. bizarre phrase to me. It's how we spend the majority of our waking hours. That's why I think at Roe, where talented people work is a gift. You have to earn that gift and you take that responsibility super seriously. To your point, when
- 59:02
- Unidentified speaker (speaker_1): you find the thing that you were meant to do, I think you stop thinking about it like work. You just follow the rabbit hole of your brain.
- 59:09
- Unidentified speaker (speaker_0): Your finance team isn't losing money on big mistakes, it's leaking through a thousand tiny decisions. Nobody's watching. Ramp puts guardrails on spending before it happens. Real-time limits, automatic rules, zero firefighting. Try it at ramp.comslash invest.
- 59:26
- Unidentified speaker (UNKNOWN): As
- 59:26
- Unidentified speaker (speaker_0): your business grows, Vanta scales with you, automating compliance and giving you a single source of truth for security and risk. Learn more at Or vanta.comslash invest.
- 59:36
- Unidentified speaker (speaker_0): Ridgeline offers one unified platform that automates a way. away the complexity across portfolio accounting, reconciliation, reporting, trading, compliance, and more, all at scale. Schedule a demo at ridgeline.ai.
- 59:48
- Unidentified speaker (speaker_0): Every investment firm is unique, and generic AI chatbots don't understand your process. Rogo is built by finance professionals. It's connected to your data, learns your process, and quickly produces client-ready client ready outputs. Check them out at rogo.com/slash. rogo.com slash invest.
- 1:00:04
- Unidentified speaker (UNKNOWN): The
- 1:00:05
- Unidentified speaker (speaker_0): best AI and software companies from OpenAI to cursor to perplexity use workOS to become enterprise ready overnight, not in months. Visit workOS.com to skip the unglamorous infrastructure work and focus on your product.
- 1:00:17
- Unidentified speaker (UNKNOWN): One of
- 1:00:18
- Unidentified speaker (speaker_0): the things that's interesting to me today is there aren't that many great new, well-known consumer businesses. Building them is extremely difficult, but when you have consumer distribution, it's one of the most powerful things in business. So if I go back to that original beachhead with Viagra, wherever the other drugs were, talk about all those aspects around that first beachhead.
- 1:00:38
- Unidentified speaker (speaker_1): It's a great question. In healthcare, there's this thing that a lot of digital health has this graveyard of startups where people focus on need and need and need alone. And I think the key that we have always believed it, Row, is we start with what patients want and find the overlap with need. It's not that they just want it and they don't need it. We start with want.
- 1:00:58
- Unidentified speaker (speaker_1): And it's very specific that it's want to start, overlap with need. Because if I went to your doctor and said, Hey, Patrick's doctor, what does Patrick need? They would say, with all of the confidence in the world, exactly what you needed. Now, if I went to them and said, Hey, what does Patrick want? Well, they'd say, I don't know, you gotta know, ask. that's so it naturally puts you in a
- 1:01:17
- Unidentified speaker (speaker_1): patient-centric position and one of selflessness and egolessness, where you are in service of what the patient wants. And that's how I think we have activated consumers in healthcare, is we are completely willing to be misunderstood. When we first started, the New And York Times called us restaurant menu medicine as if this was a bad thing. I
- 1:01:37
- Unidentified speaker (speaker_1): was like, people have great experiences. at restaurants. You go, you give a menu, and then there's prices, and then you select what you want. So I think we were very, very comfortable being wildly misunderstood as long as the patient outcomes and the patient was at the center of everything we do. People often ask us, well, how do you assess risk at the company? And I will
- 1:01:57
- Unidentified speaker (speaker_1): always say, never at the expense of a patient, always on their behalf. We will push, we will take risks. risk as a company if we are fighting on behalf of patient health outcomes. And the new thing, again, the new thing, the data, the new model, it always has a higher burden of proof as it should. So we bring the data. We've published data on the outcomes, we publish data on our side effect response times. But basically,
- 1:02:17
- Unidentified speaker (speaker_1): every single time you send a message to Rho that's routed through an LLM, we've analyzed Analyze the topic, we've analyzed the issue. If you've mentioned a side effect, that side effect gets structured. Task is created, it's assigned to a healthcare provider, an SLA is attached. And we have a 24-7 sub-30-minute response time for your side effect. That's an entirely new form of healthcare. So you
- 1:02:36
- Unidentified speaker (UNKNOWN): got
- 1:02:36
- Unidentified speaker (speaker_1): to bring the receipts if you're going to ruffle feathers. And then on the marketing side, I was in the commercials early on. It wasn't where I said, hey, I need to be a self-promotional CEO. And this is my first extended podcast ever in nine years, but it was more. actually where I was in the commercial because with marketing and how we think about a lot of these things is
- 1:02:56
- Unidentified speaker (speaker_1): there's sort of two components here. And we do this to this day. One is we talk a lot about you need data to move the brain, you need a story to move the heart, and you need both to move a human. And so that was one component to our marketing where I challenged the idea for many people of who could have erectile dysfunction. And then the second thing is with great marketing,
- 1:03:16
- Unidentified speaker (speaker_1): I do think, particularly with things that have stigma attached to them: weight loss, reproductive health, mental health, ED, whatever it may be, what our marketing does is it tries to create permission structures on behalf of people who need that product or service by doing two things: massively shifting the Overton window so that we're the
- 1:03:36
- Unidentified speaker (speaker_1): extreme, so that they never have to be. And the second is by telling stories that deeply resonate with them. So
- 1:03:42
- Unidentified speaker (speaker_2): Serena Williams
- 1:03:43
- Unidentified speaker (speaker_1): is a great example of this. She's a ambassador for a row body for GLP once. She is one of one as a human being, greatest of all time tennis player. But she's one of millions when it comes to her health journey. Mother of two was doing everything right, diet, exercising, the scale wouldn't budge, and she was having health challenges on the other side of having two kids. The number of people, I just was
- 1:04:03
- Unidentified speaker (speaker_1): speaking to a patient this week who's almost in tears saying what seeing Serena Williams did for them. They felt comfortable and they said, if Serena needs this, then it's okay if I need it. And you've seen us with the same thing with Charles Barclay, or the same thing with Chrissy Metz, or the same thing with Megan Fox and ED. Megan Fox, for a certain generation, could tell people they get to a colonoscopy and they'd be like,
- 1:04:23
- Unidentified speaker (speaker_1): done. You know? And the fact that she's like, hey, sex is an important part of our relationships. It's okay if you need support. The fact is, you're taking a step forward, and that actually shows a commitment to your partner. And I love that. So that just creates a permission structure for someone who sits there and says, Well, I don't know what my partner's gonna think. And so I think all of these things try to really touch on each one of those.
- 1:04:42
- Unidentified speaker (speaker_0): Maybe say
- 1:04:43
- Unidentified speaker (UNKNOWN): one
- 1:04:43
- Unidentified speaker (speaker_0): bit more too. I'm so intrigued by these methods about, I would phrase it as like stigma as a signpost towards latent dementia. demand, unmet demand. Yeah. What have you learned about that idea of stigma?
- 1:04:55
- Unidentified speaker (speaker_1): There's a lot of potential energy there.
- 1:04:56
- Unidentified speaker (speaker_0): Yeah.
- 1:04:56
- Unidentified speaker (speaker_1): And when there's a lot of tension on a subject, that's something that a lot of consumer founders can tap into.
- 1:05:02
- Unidentified speaker (speaker_0): Yeah.
- 1:05:02
- Unidentified speaker (speaker_1): Now, I think the way that we've tapped into that is always having what I would argue is the moral high ground. The more controversial you are, but at the same time, if you can look back and say, in the fullness of time, history will be on our side. You can be as loud and loud and loud as possible. And so that to me is like even take GLP1s. When we were
- 1:05:22
- Unidentified speaker (speaker_1): pushing, we originally had this, I put in quotation, but controversial subway campaign where the only thing that we did was show people that were clinically eligible using the medication and then set a weekly shot to lose weight. It was literally instructions and it caused this massive kerfluffle.
- 1:05:37
- Unidentified speaker (speaker_0): Why?
- 1:05:38
- Unidentified speaker (speaker_1): People were very uncomfortable. about the idea of people using injections to lose weight. And we knew that. But people misunderstood the negative health impacts of carrying excess weight. They thought of it like a shortcut. You take myths in society, like the myth of, oh, obesity is just a lack of self-discipline or willpower. And you can poke at that.
- 1:05:57
- Unidentified speaker (speaker_1): Oh, only XY or Z people need medication, or only XY XYRZ or Z people should be. treated for ED or whatever it may be. Take another one as an example relates to GLP1s, where people are oftentimes talking about how do you go off of them? When do you go off of them? And people should be able to go off medication whatever they want. They should do it safely, and there should be no judgment if they want to try and
- 1:06:17
- Unidentified speaker (speaker_1): achieve their health goals without medication. But it's very interesting in a and sign of the stigma that people want when it comes to weight loss medication. They talk about it as if they're shocked.
- 1:06:27
- Unidentified speaker (speaker_1): and they do not want people to need the medication on an ongoing basis, where unlike any other form of actual medication or behavior. So as an example, what do people think is going to happen when they stop taking their cholesterol medication? What do people think is going to happen when they stop taking birth control? Right. It's not going to be a surprise. And then as opposed to behavior too, you can't just do one push-up. You
- 1:06:47
- Unidentified speaker (speaker_1): can't eat one salad. Basically, any medication, any behavior, you need to continue to do an ongoing basis to continue to get the benefits. The fact that that makes people's stomach churn when it comes to weight loss and medications is a far greater reflection of how they feel about that. And so when there's tension in something that shouldn't
- 1:07:07
- Unidentified speaker (speaker_1): be the case, when it's just intellectually wrong and societally charged, it creates an opportunity to play with that from a societal society. way.
- 1:07:15
- Unidentified speaker (speaker_0): What have you learned about doing these campaigns? Megan Fox, I think, was the most recent one. And I remember seeing it. Obviously, you struck some major chord. What have you learned about? I'm interested in the nitty-gritty details here, like picking her versus the 10 other people you might have picked, or the nature of the visuals, or the copy, or the release, working with celebrities as a thing
- 1:07:35
- Unidentified speaker (speaker_0): to draw brand attention.
- 1:07:37
- Unidentified speaker (speaker_1): There's so much here. I'd be remiss if I didn't start by saying, This is my co-founder Simon Superpower. So I'm LARPing when I'm here talking about this. He is absolutely world-class at this. And I think you can see it in Rose's performance and brand awareness. Now, if I'm trying to channel him and echo
- 1:07:57
- Unidentified speaker (speaker_1): him here, from a celebrities perspective, yes, it's about creating permission structures, but he is very, very strict. Megan is a very unique use case, but everything about Charles and Chrissy and Serena and Trisha Paytas, and we have two or three coming out soon. All of them are on the product because it's so important to him and
- 1:08:17
- Unidentified speaker (speaker_1): to patients that they are authentically sharing their experience. And that's what he crafts the campaigns around. If you look at a Charles Barkley. commercial, it's Charles. It's unscripted. It's him in front of a camera. He's making jokes, having fun. But he's also sharing his authentic story there.
- 1:08:36
- Unidentified speaker (speaker_1): Serena comes into a shoot and she is locked in. She is going to be the best commercial shooter of all time. Literally, phones away, she's schlocked locked in, lighting, director, sound, everything, positioning. It's remarkable. The cool part. as a total side note of working with all these people, is that you see why they are who they are,
- 1:08:56
- Unidentified speaker (speaker_1): because they are to the nth degree, why they are the best in the world at what they do is very evident within minutes of meeting them. So that's just a cool thing to see. But on the celebrity fronts, it's about really finding these authentic stories that create permission structures. Why they are more useful now than even five, 10 years ago, is because the
- 1:09:16
- Unidentified speaker (speaker_1): bar to create high quality looking ads is very low with AI. What would qualify as a beautiful ad 10 years ago on Instagram that someone would have spent a ton of time on is 10 seconds now. And
- 1:09:29
- Unidentified speaker (UNKNOWN): no
- 1:09:30
- Unidentified speaker (speaker_1): money. And no money. So how do you break through the noise when everyone's just looking at pretty good looking stuff? Well, you see Charles Barkley's Barclay's face or Serena's face or Megan Fox says. Aids, you cannot replicate those in an age of guy. Yeah. So I think that that is powerful to do.
- 1:09:43
- Unidentified speaker (speaker_0): Yeah. Back to this stigma idea. What are the stigmas today that interest you? So now that first campaign, the summer campaign mount, it's like totally normal. The window has shifted. So where has the window not yet shifted where there's stigma that you find interesting?
- 1:09:57
- Unidentified speaker (UNKNOWN): Back to the earlier
- 1:09:58
- Unidentified speaker (speaker_3): question that
- 1:09:58
- Unidentified speaker (UNKNOWN): you asked
- 1:09:58
- Unidentified speaker (speaker_1): around people taking
- 1:10:00
- Unidentified speaker (speaker_3): medications
- 1:10:01
- Unidentified speaker (speaker_1): prophylactically or on the early earlier side of what would be considered early is fascinating to me. Because first of all, on the way here, I must have passed 15 bars from my office.
- 1:10:13
- Unidentified speaker (UNKNOWN): And
- 1:10:13
- Unidentified speaker (speaker_1): that is literally an exchange of poison for entertainment. Full stop. You turn 21, you can do that. And then half of my TV ads are about it. And then you take medicine, something that has literally it is the most stuff. studied thing that humans put in their body, in Barno. And there's a randomized control trial for it. There's clear risks and benefits.
- 1:10:33
- Unidentified speaker (speaker_1): And then by the way, in order to get it, you have to talk to an expert and engage with them. And in order to keep getting it, you have to keep talking to them. But then the idea of advertising that on TV is like, whoa, whoa, whoa, whoa, whoa. Versus poison, totally fine. Cheeseburgers, totally fine. And I believe I love cheeseburgers, but this difference where those are
- 1:10:51
- Unidentified speaker (speaker_1): obviously a health net negative. The question is whether enjoyment outweighs that. And we can have that conversation in society. But over here, there's at least a probabilistic equation of whether the benefits dramatically outweigh the risks. Someone is engaging with an expert in that and they're doing it on an ongoing basis. So to me, this idea, like sometimes when I tell people that I'm on these medications, they're shocked as I see
- 1:11:11
- Unidentified speaker (speaker_1): them literally drink poison. And that's not a knock on that at all. Someone should be able to do that. But it's the difference between those two that I find quite surprising.
- 1:11:22
- Unidentified speaker (speaker_0): Are there other things that I guess the prompt would be like the hottest takes you have, differences of opinion versus your peers versus the industry versus the world, where you feel most alone in what you believe?
- 1:11:36
- Unidentified speaker (UNKNOWN): I
- 1:11:36
- Unidentified speaker (speaker_1): feel very lucky, but I think that there's a lot of
- 1:11:39
- Unidentified speaker (speaker_1): I understand why there is, but there's a lot of obsession over the founder. And I think that maybe other founders don't. But I feel like I have an incredible support network. And I think in particular, I would say my spouse. I don't know that founders who have very, very supportive
- 1:11:59
- Unidentified speaker (speaker_1): spouses talk about it a lot, to be honest. Cleo and I have taken turns. Actually, we met very, very young. We met when I was 19 and she was 17. And we started dating a few years later. We've been together 13 years. And in New York City, we grew up together. We have taken turns financially supporting one another, actually. So when I first started Roe, we were living in a friend's apartment together. We had the smaller
- 1:12:19
- Unidentified speaker (speaker_1): room, he had the master. She was on a journalist salary, buying both of us breakfast, lunch, and dinner. And so I would not be the person I am today. or be able to run Roe if we weren't together. And so I think there's just a lot of people along the way in these journeys that it's usually just assigned to one person. I would say the same thing with our team. Our team is
- 1:12:39
- Unidentified speaker (speaker_1): absolutely incredible. So that's probably one of the things that I think there's a lot of founders that a lot of worship they believe their shit doesn't stink and it's kind of exhausting.
- 1:12:48
- Unidentified speaker (speaker_0): Not a lot of hard ass founder wife guys.
- 1:12:51
- Unidentified speaker (speaker_1): There you go. It's true. That's true. It seems weak seems macaroon soft, but I actually think it's the opposite.
- 1:12:57
- Unidentified speaker (speaker_0): It's been incredibly fun. It's so cool to hear all the lessons that you've learned doing this twice, I guess, if you refounded it halfway through. And I do think that these tailwinds that you've taught us about today are the two most interesting in the entire world. And I sure hope they keep blowing. You know my traditional closing question when I do this? what is the kindest thing that anyone's ever done for
- 1:13:17
- Unidentified speaker (speaker_0): you?
- 1:13:17
- Unidentified speaker (speaker_1): So I've thought about this because I listen to your podcast all the time. And I think I was inspired by your answer, which is when I was 15 years old, I was at boarding school and I was very homesick. I missed my parents tremendously. And they came to visit me, and my dad and mom watched me play sports and when they took me out to dinner.
- 1:13:37
- Unidentified speaker (speaker_1): And my way of expressing my love to them because I was homesick was I was kind of mean. And my parents knew it. They knew that it was just me acting out in that way. And when they were leaving, my dad asked my mom to drive. And my mom has an autoimmune disease, and so he normally drives. And so, again, back
- 1:13:57
- Unidentified speaker (speaker_1): to what we said before, sometimes you realize things in retrospect. I didn't realize at the time that something was different explicitly. but implicitly I did. I was like, that's odd. Then my dad got in the passenger seat and he rolled down the window and something in his voice changed where he looked at me and he just said, Tell me you love me. And I I completely switched and I said, Of course I love you. I love you so much. And
- 1:14:17
- Unidentified speaker (speaker_1): said good, I love you too. And he drove away and he looks at my mom. I've only found this out later. He looks at my mom and he says, Take me to the hospital. I'm having my fourth heart attack. And I asked him after. He fortunately made it. He didn't think he was going to make it. I asked him after. I was like, hey, like seconds matter. Like, what were you doing? And he goes, Well, first, it was two seconds and I didn't think I was going to make it. And the
- 1:14:36
- Unidentified speaker (speaker_1): second is I didn't want your last words to me to be an argument. I wanted them to be I love you. And it's like one of the most selfless things that he could have done, but what it did for me, I think the gift that he gave me was to never let the love that you feel
- 1:14:56
- Unidentified speaker (speaker_1): for people go unspoken. And so to this day, when I hang up with him, my friends, I will say I love you. And I got my co-founder. It took me six years. I say I love you to him when we hang up a Google Hangout. When I hang up on the phone, I tell him I love you. And I do, I love him. And so I think at such a
- 1:15:16
- Unidentified speaker (speaker_1): young age, feeling the fragility of that and being able to put your hand on the stove with unspoken love and not doing that ever again is something that I think I will always cherish for him.
- 1:15:27
- Unidentified speaker (speaker_0): Incredible story, very unique. I've done a lot of these, haven't heard one quite like that. Thank you so much for doing it. Thank
- 1:15:32
- Unidentified speaker (UNKNOWN): you. If
- 1:15:33
- Unidentified speaker (speaker_3): you enjoyed this episode, visit Colossus.com. You'll find every episode of this podcast complete with hand-edited transcripts. You can also subscribe to Colossus, our quarterly print, digital, and private audio publication featuring in-depth profiles of the founders, investors, and companies that we admire most. Learn more at Colossus.com/slash subscribe.
- 1:15:54
- Unidentified speaker (speaker_1): Patrick O'Shaughnessy is the CEO of Positive Sum. All opinions expressed by Patrick and podcast guests are solely their own opinions and do not reflect the opinion. of Positive Sum. This podcast is for informational purposes only and should not be relied upon as a basis for investment decisions.
- 1:16:09
- Unidentified speaker (UNKNOWN): Clients
- 1:16:10
- Unidentified speaker (speaker_0): of Positive Sum may maintain positions in the securities discussed in this podcast.
- 1:16:14
- Unidentified speaker (UNKNOWN): To
- 1:16:14
- Unidentified speaker (speaker_0): learn more, visit psum.vc.
- 1:16:37
- Unidentified speaker (UNKNOWN): You
- 1:16:37
- Unidentified speaker (speaker_3): know how small advantages compound over time, that's true in investing and just as true in how you run your company. Your spending system is your capital allocation strategy. Ramp makes it smarter by default, better data, better decisions, better economics over time. See how. at ramp.com/slash invest. As your business grows, Vanta scales with you, automating compliance and giving you a single source of truth
- 1:16:57
- Unidentified speaker (speaker_3): for security and risk. Learn more at vanta.com/slash invest. The best AI and software companies, from OpenAI to cursor to perplexity, use WorkOS to become enterprise ready overnight, not in months. Visit workos.com to skip the unglamorous infrastructure work and focus on your product. Ridgeline is redefined. redefining asset management technology as a true partner, not just a
- 1:17:17
- Unidentified speaker (speaker_3): software vendor. They've helped firms 5x in scale, enabling faster growth, smarter operations, and a competitive edge. Visit Ridgelineapps.com to see what they can unlock for your firm. Every investment firm is unique and generic AI doesn't understand your process. Rogo does. It's an AI platform built specifically for Wall Street, connected to your data, understanding your process, and
- 1:17:37
- Unidentified speaker (speaker_3): producing real outputs. Check them out at rogo.ai slash invest.
More from Invest Like the Best with Patrick O'Shaughnessy
Ramtin Naimi on the State of Venture Investing - [Invest Like the Best, EP.499]
Episode discussion: Ramtin Naimi on VC market speed, 'cuck tranches', and why proactive investing in non-obvious markets generates alpha
Speakers’ claims: Ramtin Naimi describes the current venture market as extremely fast-paced, with deal cycles compressed and top companies receiving disproportionate demand. He highlights a 'cuck tranche' phenomenon where late entrants pay 3x-5x premiums to join primary rounds, driven by capital-intensive needs in AI. Naimi contrasts current high-quality, product-market-fit companies with the 2021 SaaS boom, noting that while valuations are high, the underlying business fundamentals are stronger. He argues that proactive investing in non-obvious markets yields better returns than chasing consensus late-stage deals. Naimi also discusses the impact of LP concentration in mega-companies and the rising costs of compute for private AI labs.
Martin Casado on Frontier Model Economics, AI's Slowdown, and the Cursor Deal - [Invest Like the Best, EP.498]
Episode discussion: Martin Casado on Frontier AI Economics, Infrastructure Disruption, and Strategic M&A Dynamics
Speakers’ claims: Marc Andreessen Horizon Ventures partner Martin Casado categorizes venture investing into four mindsets, advocating for a 'productive' approach focused on technical infrastructure rather than traditional financial metrics. He argues that frontier AI models have short lifespans of 3-6 months and that current market leaders hold ~80% share due to unsaturated demand, though this may shift if the market slows. Casado identifies physical hardware, power, and materials as the primary bottlenecks in AI infrastructure, predicting consolidation among large providers. He also details the strategic M&A dynamics behind the Cursor acquisition, emphasizing trust and alignment over adversarial tactics.